1.0-M gadobutrol versus 0.5-M gadoterate for peripheral magnetic resonance angiography: A prospective randomized controlled clinical trial

    loading  Checking for direct PDF access through Ovid

Abstract

Purpose

To perform a quantitative and qualitative comparison of gadobutrol and gadoterate in three-station contrast enhanced magnetic resonance angiography (CE-MRA) of the lower limbs.

Materials and Methods

In this prospective randomized controlled trial, 52 patients with leg ischemia were randomly assigned to one of two groups receiving either gadobutrol (1.0 mmol Gd/mL, 15 mL) or gadoterate (0.5 mmol Gd/mL, 30 mL). Three-station 3D CE-MRAs from the pelvis to the ankles were performed with moving-table technique on a 1.5T MR scanner. Injection time was identical in both groups. Signal-to-noise (SNR) and contrast-to-noise ratios (CNR) were calculated for 816 arteries. Contrast quality in 1196 vessel segments was evaluated separately by two blinded readers on a three-point scale.

Results

Mean SNR (61.8 ± 7.8 for gadobutrol vs. 61.9 ± 9.1 for gadoterate, P = 0.257), CNR (52.8 ± 9.1 vs. 52.8 ± 10.7, P = 0.154), and qualitative ranking (1.41 vs. 1.44, P = 0.21) for all vessels did not differ significantly between the two patient groups. The overall quality was good in 90.4% with gadoterate and 94.2% with gadobutrol (P = 0.462).

Conclusion

High-concentration gadobutrol allows neither a higher CNR nor any qualitative advantage over the ordinary unspecific Gd agent gadoterate when the same Gd load and injection times are used in multistation CE-MRA of the peripheral arteries. J. Magn. Reson. Imaging 2008;27:1399–1405. © 2008 Wiley-Liss, Inc.

Related Topics

    loading  Loading Related Articles